Next Generation Sequencing to Evaluate Breast Cancer Subtypes and Genomic Predictors of Response to Therapy in the Preoperative Setting for Stage II-III Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Trastuzumab (Primary) ; Carboplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Paclitaxel; Pertuzumab
- Indications Advanced breast cancer; Early breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 03 Aug 2017 Status changed from active, no longer recruiting to completed.
- 10 Nov 2016 Status changed from suspended to active, no longer recruiting.